Adar1 Capital Management, Llc Acquires 7,798 Shares of NextCure (NASDAQ:NXTC) Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 7,798 shares of the business’s stock in a transaction dated Monday, July 27th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $38,990.00. Following the acquisition, the insider directly owned 383,456 shares in the company, valued at $1,917,280. This represents a 2.08% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc acquired 3,410 shares of NextCure stock. The stock was acquired at an average cost of $5.00 per share, with a total value of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc acquired 6,400 shares of NextCure stock. The stock was acquired at an average price of $4.95 per share, with a total value of $31,680.00.

NextCure Trading Up 0.2%

Shares of NASDAQ:NXTC opened at $5.03 on Friday. The stock has a market capitalization of $18.17 million, a PE ratio of -0.29 and a beta of 1.42. NextCure, Inc. has a 1 year low of $1.55 and a 1 year high of $15.74. The firm has a fifty day moving average price of $3.56 and a 200 day moving average price of $8.72.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, sell-side analysts forecast that NextCure, Inc. will post -7.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NextCure in a report on Wednesday, July 15th. Wall Street Zen lowered shares of NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $19.00.

Institutional Investors Weigh In On NextCure

Several hedge funds and other institutional investors have recently made changes to their positions in NXTC. Marshall Wace LLP bought a new position in shares of NextCure in the fourth quarter worth about $160,000. Millennium Management LLC bought a new stake in NextCure during the 4th quarter valued at approximately $185,000. Geode Capital Management LLC boosted its stake in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the period. Cable Car Capital LP boosted its stake in NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after buying an additional 5,300 shares during the last quarter. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.